A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

Potential Implication of Residual Viremia in Patients on Effective Antiretroviral Therapy

(2015) Gautam K. Sahu   AIDS RESEARCH AND HUMAN RETROVIRUSES

Understanding HIV Latency: The Road to an HIV Cure

(2015) Matthew S. Dahabieh et al.   Annual Review of Medicine

HIV Eradication: Combinatorial Approaches to Activate Latent Viruses

(2014) Elisa De Crignis et al.   Viruses-Basel

Therapeutic and prophylactic DNA vaccines for HIV-1

(2013) Lorenzo Antonio Ramirez et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical applications of attenuated MVA poxvirus strain

(2013) Carmen Elena Gómez et al.   Expert Review of Vaccines

Immune interventions in HIV infection

(2013) Guislaine Carcelain et al.   IMMUNOLOGICAL REVIEWS

Harnessing CD4+ T cell responses in HIV vaccine development

(2013) Hendrik Streeck et al.   NATURE MEDICINE

Vaccine and immunotherapeutic interventions

(2013) Giuseppe Pantaleo et al.   Current Opinion in HIV and AIDS

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

(2013) Thomas Rasmussen et al.   Human Vaccines & Immunotherapeutics

NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients

(2012) Alexandre Harari et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?

(2012) Guido Vanham et al.   Retrovirology

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors

(2012) Juan García-Arriaza et al.   VIRUS RESEARCH

Therapeutic vaccines against HIV infection

(2012) Felipe García et al.   Human Vaccines & Immunotherapeutics

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

The successes and failures of HIV drug discovery

(2011) Chie Hashimoto et al.   Expert Opinion on Drug Discovery

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens

(2011) C. E. Gomez et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

(2011) Felipe García et al.   VACCINE

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays

(2010) S Kutscher et al.   GENE THERAPY

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

(2010) José Luis Nájera et al.   PLoS One

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

(2010) Juan García-Arriaza et al.   PLoS One

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

(2010) Sarah Howles et al.   VACCINE

Heterologous prime–boost vaccination

(2009) Shan Lu   CURRENT OPINION IN IMMUNOLOGY

The Spanish HIV BioBank: a model of cooperative HIV research

(2009) Isabel Garcia-Merino et al.   Retrovirology

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

(2008) Thomas C. Greenough et al.   VACCINE